Table 3 Vaccine efficacy estimates by baseline serostatus, serotype and age-group obtained with imputation

From: Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning

 

All ages (2–16 years)

2–8-year olds

9–16 year olds

 

sero+

sero−

p-value

sero+

sero−

p-value

sero+

sero−

p-value

 DENV1

0.59 (0.38, 0.74)

0.45 (0.22, 0.64)

0.309

0.51 (−0.12, 0.81)

0.36 (−0.10, 0.66)

0.624

0.62 (0.42, 0.77)

0.52 (0.26, 0.70)

0.469

 DENV2

0.54 (0.33, 0.73)

−0.08 (−0.70. 0.38)

0.029

0.34 (−0.17, 0.69)

−0.01 (−0.99, 0.56)

0.426

0.63 (0.44, 0.79)

−0.18 (−1.41, 0.36)

0.085

 DENV3

0.74 (0.61, 0.84)

0.67 (0.38, 0.90)

0.630

0.68 (0.21, 0.95)

0.73 (0.10, 1.00)

0.885

0.75 (0.62, 0.85)

0.64 (0.27, 0.89)

0.485

 DENV4

0.88 (0.80, 0.95)

0.50 (0.12, 0.72)

0.019

0.77 (0.37, 0.97)

0.22 (−1.28, 0.356)

0.379

0.91 (0.84, 0.97)

0.59 (0.11, 0.81)

0.070

  1. Mean and 95% CI (within parentheses) of the vaccine efficacy estimates by baseline serostatus, serotype and age-group generated with imputation and significance of the statistical difference in vaccine efficacy between baseline seropositive and baseline seronegative subjects against each serotype in each age-group. The p-values were obtained using the Pearson’s chi-squared test. sero+ stands for seropositive; sero− stands for seronegative. Significant (<0.05) p-values and the corresponding estimates are in bold
Back to article page